Operating Cash Flow per Share: A measure of financial performance calculated as operating cash flow, expressed on a per share basis. Calculated as: Cash Flow from Operations / Weighted Average Shares Outstanding (Diluted)
G1 Therapeutics (GTHX) had Operating Cash Flow per Share of $-0.74 for the most recently reported fiscal year, ending 2023-12-31.
Income Statement Financials | |
$82.51M |
|
$-47.97M |
|
$7.20M |
|
$75.32M |
|
$122.04M |
|
$-39.53M |
|
$-5.33M |
|
$-44.85M |
|
$-44.85M |
|
$-47.97M |
|
$-47.97M |
|
$-47.97M |
|
$-47.97M |
|
$-39.53M |
|
$-37.54M |
|
51.73M |
|
51.73M |
|
$-0.93 |
|
$-0.93 |
|
Balance Sheet Financials | |
$114.95M |
|
$1.48M |
|
$6.59M |
|
$121.54M |
|
$29.72M |
|
$51.56M |
|
$56.44M |
|
$86.15M |
|
$35.39M |
|
$35.39M |
|
$35.39M |
|
51.93M |
|
Cash Flow Statement Financials | |
$-38.34M |
|
$2.81M |
|
$-26.91M |
|
$94.91M |
|
$32.47M |
|
$-62.44M |
|
$14.51M |
|
-- |
|
-- |
|
Fundamental Metrics & Ratios | |
3.87 |
|
-- |
|
-- |
|
0.59 |
|
1.46 |
|
91.28% |
|
-47.91% |
|
-47.91% |
|
-45.50% |
|
-54.36% |
|
-58.13% |
|
$-38.34M |
|
-- |
|
-- |
|
-- |
|
0.68 |
|
0.58 |
|
6.50 |
|
56.12 |
|
-135.55% |
|
-135.55% |
|
-39.47% |
|
-55.17% |
|
$0.68 |
|
$-0.74 |
|
Operating Cash Flow per Share |
$-0.74 |